Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.340
-0.080-2.34%
Volume:2.64M
Turnover:8.90M
Market Cap:2.27B
PE:-6.57
High:3.430
Open:3.420
Low:3.280
Close:3.420
52wk High:8.160
52wk Low:0.740
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:0.76
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.508
ROE:-25.98%
ROA:-13.05%
PB:2.62
PE(LYR):-6.57
PS:23.84

Loading ...

Antengene (06996) Releases January 2026 Monthly Return: No Changes to Issued Shares

Bulletin Express
·
Feb 04

Antengene Showcases Pipeline Progress at J.P. Morgan Healthcare Conference

Reuters
·
Jan 16

Antengene Leads The Charge In Global With 2 Other Penny Stocks

Simply Wall St.
·
Jan 08

BRIEF-Antengene Says Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio For Relapsed Or Refractory DLBCL

Reuters
·
Dec 17, 2025

EU Plans to Ease Combustion Engine Ban; Dow and S&P Extend Losses for Third Day

Stock News
·
Dec 17, 2025

ANTENGENE-B (06996): Xpovio® Approved in Malaysia for New Indication in Treating Diffuse Large B-Cell Lymphoma

Stock News
·
Dec 17, 2025

Antengene Corp - Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio for Relapsed or Refractory Dlbcl

THOMSON REUTERS
·
Dec 17, 2025

Antengene Wins Malaysian Approval for XPOVIO in Diffuse Large B-Cell Lymphoma

Reuters
·
Dec 17, 2025

BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample

Stock News
·
Dec 05, 2025

Antengene (06996) Announces November 2025 Monthly Return on Movements in Securities

Bulletin Express
·
Dec 04, 2025

Antengene Gets HK Government Nod for Two Applications of Tumor Drug; Shares Jump 5%

MT Newswires Live
·
Dec 04, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Antengene (6996) Announces Hong Kong Approval of Two Additional XPOVIO® Indications

Bulletin Express
·
Dec 03, 2025

ANTENGENE-B (06996): XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Stock News
·
Dec 03, 2025

BRIEF-Antengene Corp Says Xpovio Approved In Hong Kong For Two Additional Indications

Reuters
·
Dec 03, 2025

Antengene Wins Hong Kong Approval for XPOVIO in Multiple Myeloma and Lymphoma

Reuters
·
Dec 03, 2025

Antengene Corp - Xpovio Approved in Hong Kong for Two Additional Indications

THOMSON REUTERS
·
Dec 03, 2025

BRIEF-Antengene Corp Says China's NMPA Approves IND Application For ATG-022 Study

Reuters
·
Dec 02, 2025

BRIEF-Antengene Announces IND Approval In China For Phase Ib/II Study Of ATG-022 In Combination With Keytruda

Reuters
·
Dec 02, 2025

Antengene (6996.HK) Announces IND Approval in China for Phase Ib/II Study of ATG-022 With KEYTRUDA® ± Chemotherapy

Bulletin Express
·
Dec 02, 2025